Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple Myeloma

29 Jul 2024

Abstract excerpt

Multiple myeloma (MM) first-line treatment algorithms include immuno-chemotherapy (ICT) induction, high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) consolidation, followed by lenalidomide maintenance. After these initial therapies, most patients suffer a disease relapse and require subsequent treatment lines including ICT, additional HDCT and ASCT, or novel immunotherapies. The presence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39194701
DOI: 10.3390/cimb46080484

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple MyelomaPMID 39194701Read ↗

PPM1D in Solid and Hematologic Malignancies: Friend and Foe?Semantic proximity Read ↗

Protein phosphatase, Mg2+/Mn2+-dependent 1D (PPM1D) mutations in haematological cancer.Semantic proximity Read ↗

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic ChemotherapySemantic proximity Read ↗

Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersSemantic proximity Read ↗

Genomic Determinants and Clinical Outcomes of Second Primary Hematological Malignancies in Patients with B-cell Cancers.Semantic proximity Read ↗

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cellsSemantic proximity Read ↗

Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.Semantic proximity Read ↗

The role of PPM1D in cancer and advances in studies of its inhibitorsSemantic proximity Read ↗

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.Semantic proximity Read ↗

Characterization of rare germline variants in familial multiple myelomaSemantic proximity Read ↗

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.Semantic proximity Read ↗

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.